The overall objective of the PNNL Proteome Characterization Center (PCC) is to integrate genomic information with proteomic technologies to comprehensively characterize the proteome and post-translational modifications (PTMs) as well as the functional interaction of proteins in signaling networks in cancers. As one of the PCCs in the current Clinical Proteomic Tumor Analysis Consortium (CPTAC) program, PNNL successfully applied advanced proteomics capabilities and expertise to the comprehensive proteogenomic and phosphoproteomic characterization of ovarian high-grade serous carcinomas from The Cancer Genome Atlas, and has developed novel mass spectrometric approaches to facilitate the analysis of intact proteins, low stoichiometry PTMs, and extremely small samples. The planned PNNL PCC will build on these achievements and contribute to the success of the CPTAC network by characterizing multiple new tumor types assigned by CPTAC, using both the proven standardized, multiplexed discovery and targeted confirmatory workflows as well as introducing novel technologies and platforms, as appropriate, to improve proteomic measurements. Both human biospecimens and preclinical models provided by NCI will be analyzed. The Discovery Research Arm will comprehensively characterize the proteome and multiple PTM-omes in human biospecimens and preclinical samples of 2-3 cancers with the validated advanced proteomics platforms, integrated workflows and informatics tools, using highly multiplexed isobaric labeling and state-of- the-art liquid chromatography-tandem mass spectrometry instrumentation at a throughput of up to 300 samples per year. The Confirmatory Research Arm will verify the impact of genomic variation on the changes in proteome and PTM-omes with validated targeted proteomics platforms (e.g., multiple reaction monitoring), peptide standards and quality assurance. Up to 100 highly specific, multiplexed targeted proteomics assays for both proteins and PTMs will be developed each year for the confirmatory studies using up to 150 samples per year. We will also refine and validate several developmental strategies and platforms at the PNNL PCC leveraging our on-going technology development in areas such as ultrafast gas phase separations and small- sized sample analysis platforms and methodologies to further improve the throughput and sensitivity in both the discovery and confirmatory studies. The PNNL PCC will work closely with the other PCCs, Proteogenomic Data Analysis Centers and Proteogenomic Translational Research Centers in the CPTAC network on data integration and bioinformatics analysis, as well as translational applications.
Cancer is a molecular disease that often originates in genomic abnormalities, however these genome-level defects exerts its functional significance at the level of proteins, and these alterations have functional consequences that impact early detection, treatment, prognosis, and prevention. Coordinating within the Clinical Proteomic Tumor Analysis Consortium network, the PNNL Proteome Characterization Center will comprehensively characterize the protein-level changes in cancer and healthy states by combing both proteome- and genome-level information, contributing to a more unified understanding of cancer biology with translational potential, e.g., development of new cancer diagnostic, prevention, and treatment strategies.
|Chouinard, Christopher D; Nagy, Gabe; Webb, Ian K et al. (2018) Improved Sensitivity and Separations for Phosphopeptides using Online Liquid Chromotography Coupled with Structures for Lossless Ion Manipulations Ion Mobility-Mass Spectrometry. Anal Chem 90:10889-10896|
|Rodland, Karin D; Piehowski, Paul; Smith, Richard D (2018) Moonshot Objectives: Catalyze New Scientific Breakthroughs-Proteogenomics. Cancer J 24:121-125|
|Yi, Lian; Shi, Tujin; Gritsenko, Marina A et al. (2018) Targeted Quantification of Phosphorylation Dynamics in the Context of EGFR-MAPK Pathway. Anal Chem 90:5256-5263|
|Piehowski, Paul D; Petyuk, Vladislav A; Sontag, Ryan L et al. (2018) Residual tissue repositories as a resource for population-based cancer proteomic studies. Clin Proteomics 15:26|
|Garabedian, Alyssa; Benigni, Paolo; Ramirez, Cesar E et al. (2018) Towards Discovery and Targeted Peptide Biomarker Detection Using nanoESI-TIMS-TOF MS. J Am Soc Mass Spectrom 29:817-826|
|Mertins, Philipp; Tang, Lauren C; Krug, Karsten et al. (2018) Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nat Protoc 13:1632-1661|
|Shi, Tujin; Gaffrey, Matthew J; Fillmore, Thomas L et al. (2018) Facile carrier-assisted targeted mass spectrometric approach for proteomic analysis of low numbers of mammalian cells. Commun Biol 1:103|
|Zhou, Jian-Ying; Chen, Lijun; Zhang, Bai et al. (2017) Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. J Proteome Res 16:4523-4530|
|Song, Ehwang; Gao, Yuqian; Wu, Chaochao et al. (2017) Targeted proteomic assays for quantitation of proteins identified by proteogenomic analysis of ovarian cancer. Sci Data 4:170091|
|Wang, Sheng; Yang, Feng; Petyuk, Vladislav A et al. (2017) Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease. J Pathol 243:78-88|
Showing the most recent 10 out of 12 publications